Premium
Romosozumab for the treatment of severe osteoporosis
Author(s) -
Chaplin Steve
Publication year - 2020
Publication title -
prescriber
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.106
H-Index - 3
eISSN - 1931-2253
pISSN - 0959-6682
DOI - 10.1002/psb.1851
Subject(s) - medicine , osteoporosis , intensive care medicine
Romosozumab (Evenity) is a new monoclonal antibody therapy for severe osteoporosis in postmenopausal women at high risk of fracture. This article outlines its indications, clinical trial efficacy and side‐effects.